Parisi Gray Wealth Management decreased its holdings in Allergan plc (NYSE:AGN) by 23.7% in the 1st quarter, HoldingsChannel reports. The fund owned 463 shares of the company’s stock after selling 144 shares during the quarter. Parisi Gray Wealth Management’s holdings in Allergan were worth $68,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in the business. BlackRock Inc. grew its holdings in Allergan by 2.9% in the fourth quarter. BlackRock Inc. now owns 21,466,017 shares of the company’s stock valued at $2,869,149,000 after purchasing an additional 600,535 shares during the last quarter. Oregon Public Employees Retirement Fund raised its holdings in shares of Allergan by 14,208.8% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 20,762,744 shares of the company’s stock worth $155,000 after purchasing an additional 20,617,639 shares during the period. Artisan Partners Limited Partnership raised its holdings in shares of Allergan by 6.5% in the 1st quarter. Artisan Partners Limited Partnership now owns 6,767,753 shares of the company’s stock worth $990,867,000 after purchasing an additional 410,746 shares during the period. Longview Partners Guernsey LTD raised its holdings in shares of Allergan by 288.6% in the 4th quarter. Longview Partners Guernsey LTD now owns 6,026,108 shares of the company’s stock worth $805,450,000 after purchasing an additional 4,475,447 shares during the period. Finally, Janus Henderson Group PLC raised its holdings in shares of Allergan by 27.6% during the 1st quarter. Janus Henderson Group PLC now owns 5,855,576 shares of the company’s stock valued at $857,312,000 after buying an additional 1,265,742 shares during the period. Hedge funds and other institutional investors own 80.29% of the company’s stock.
Several equities research analysts recently commented on AGN shares. Wells Fargo & Co reiterated a “buy” rating and set a $189.00 target price (down from $202.00) on shares of Allergan in a report on Thursday, March 7th. JPMorgan Chase & Co. restated an “overweight” rating and set a $200.00 price objective on shares of Allergan in a research note on Thursday, March 7th. They noted that the move was a valuation call. Stifel Nicolaus restated a “hold” rating and set a $175.00 price objective on shares of Allergan in a research note on Thursday, March 7th. Credit Suisse Group lowered their price objective on Allergan from $161.00 to $155.00 and set a “neutral” rating for the company in a research note on Thursday, March 7th. Finally, ValuEngine upgraded Allergan from a “strong sell” rating to a “sell” rating in a research note on Thursday, March 7th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $175.30.
Allergan (NYSE:AGN) last released its quarterly earnings data on Tuesday, May 7th. The company reported $3.79 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.55 by $0.24. Allergan had a positive return on equity of 8.45% and a negative net margin of 45.94%. The business had revenue of $3.60 billion during the quarter, compared to analyst estimates of $3.55 billion. During the same quarter in the previous year, the firm posted $3.74 EPS. The business’s revenue for the quarter was down 2.0% compared to the same quarter last year. On average, sell-side analysts predict that Allergan plc will post 16.68 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Tuesday, May 14th will be given a dividend of $0.74 per share. The ex-dividend date of this dividend is Monday, May 13th. This represents a $2.96 dividend on an annualized basis and a yield of 2.51%. Allergan’s dividend payout ratio is currently 17.74%.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.